Findings demonstrate prognostic value of ASXL1 and KRAS co-mutation in acute myeloid leukemia, suggesting a new ultra-adverse-risk subtype.
These results demonstrate the independent prognostic value of ASXL1mut/KRASmut co-mutation and define a novel ultra-adverse-risk subtype of acute myeloid leukemia.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: